
|Articles|January 1, 2004
Alcon rings NYSE bell; anecortave trials begin
New York-Tim Sear, Alcon Inc.'s chairman, president, and chief executive officer, rang the closing bell of the New York Stock Exchange at 4 p.m. Dec. 4 to celebrate the company's dramatic rise in stock price since its initial public offering.
Advertisement
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
TearSolutions advances Lacripep into phase 2 following dual FDA designations in neurotrophic keratitis
2
Oculis phase 3 DIAMOND trials miss vision endpoints in diabetic macular edema
3
Opuviz aflibercept biosimilar launches in Europe for retinal diseases
4
Study links alcohol consumption to earlier advanced presbyopia in men
5





















